|
|||||
|
|
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) |
|
| Authors: | J D Leverson H Zhang J Chen S K Tahir D C Phillips J Xue P Nimmer S Jin M Smith Y Xiao P Kovar A Tanaka M Bruncko G S Sheppard L Wang S Gierke L Kategaya D J Anderson C Wong J Eastham-Anderson M J C Ludlam D Sampath W J Fairbrother I Wertz S H Rosenberg C Tse S W Elmore A J Souers |
| Institution: | 1.Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA;2.Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA |
| Abstract: | |
| Keywords: | |